Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

Following FDA Approval, Agreement will Broaden Access to

Cholesterol-Reducing Medicine

PHILADELPHIA and WHITEHOUSE STATION, N.J., Nov. 26 /PRNewswire/ -- GlaxoSmithKline, Philadelphia, PA, USA (GSK) and Merck & Co., Inc., Whitehouse Station, NJ, USA (Merck), announced today that they have entered into an agreement for over-the-counter (OTC) marketing rights for MEVACOR(R) (lovastatin). Under the agreement, GSK will have exclusive rights to market non-prescription MEVACOR in the United States. Terms of the agreement are confidential but include milestone and royalty payments from GSK to Merck.

MEVACOR was introduced in the United States in 1987 by Merck as the first in a class of cholesterol-reducing medicines known as "statins". The U.S. patent for MEVACOR expired in 2001.

Commenting on the agreement, JP Garnier, chief executive officer, GlaxoSmithKline said, "This new partnership with Merck will enable GSK to address the important public health issue of high cholesterol and help patients better manage their health. OTC Mevacor will be a dynamic new addition to our fast-growing over-the-counter business and is further evidence of GSK's ability to partner in new OTC switch opportunities."

"With MEVACOR, Merck pioneered the development of cholesterol-lowering medicines known as "statins" which are recognized worldwide and remain the standard of care today," said Richard T. Clark, chief executive officer, Merck. "We are pleased to be able to partner with GSK as a way to bring MEVACOR directly to consumers in the United States."

Application for OTC MEVACOR to be reviewed by FDA

The new drug application (NDA) for OTC MEVACOR will be reviewed by the U.S. Food and Drug Administration (FDA) in a joint meeting of the Nonprescription Drugs Advisory Committee (NDAC) and the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) on December 13. The NDA, filed by Merck, is seeking approval of
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... York, New York (PRWEB) August 20, 2014 ... with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... LLP notes that two U.S. Senators from New York ... to seek a recall of the devices. In a ... Schumer, both Democrats, also implored the agency to seriously ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
(Date:8/20/2014)... Reinberg HealthDay Reporter TUESDAY, ... that dismantles a baby,s immune system is twice as common ... million infants says. This is the first evaluation of ... condition known as severe combined immunodeficiency (SCID), or "Bubble Boy" ... this condition by the boy in the bubble, who was ...
(Date:8/20/2014)... Santa Rosa, CA (PRWEB) August 20, 2014 ... is the 12 per diode panel band perfect spectrum that ... plants are most likely to use during photosynthesis. A ... spectral bands is that they almost exclusively reside between 440-480 ... 620-680 on the red side of the spectrum. The KIND ...
(Date:8/20/2014)... 2014 Braverman Eye Center is now ... their experienced surgeons trained in PresbyLasik. The Braverman Eye ... lost or inaccurate vision. Their diligent service and adoption ... making it possible for Presbyopia patients to have better ... in people in the age group of 40 to ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:'Bubble Boy' Disease May Be More Common Than Thought 2Health News:'Bubble Boy' Disease May Be More Common Than Thought 3Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2Health News:Braverman Eye Center Now Offers Multifocal PresbyLasik in Florida by Trained Surgeons 2
... for young people do not always provide the same quality ... As our population ages and requires more healthcare, hospitals need ... over 65s and implement programs to meet their distinct needs, ... St. Michael,s Hospital. The study, published in the June ...
... (HealthDay News) -- People who seek treatment in an emergency ... likely to be readmitted to the hospital as those who ... The finding suggests that emergency departments can help reduce the ... were to present the study Friday at the Society for ...
... Reinberg HealthDay Reporter , THURSDAY, June 2 ... Americans to eat healthier meals and fight the obesity ... icon called MyPlate. MyPlate replaces the U.S. Department ... but had become too complicated in ensuing years, many ...
... conserving therapy for women 70 years and older with ... opting for radioactive implants and those with estrogen positive ... an abstract being presented at the American Society of ... University Hospital researchers on Saturday, June 4. The ...
... are one step closer to helping millions of people ... or damage from treatment of diseases. The ... Oral Health and Rehabilitation, UofL School of Dentistry, and ... the salivary gland. The National Institutes of Health supported ...
... 2 (HealthDay News) -- Obesity and insulin resistance constitute a ... according to a new study that found drinking modest amounts ... condition. For their study, published online May 23 in ... people to either abstain from alcohol or drink one (women) ...
Cached Medicine News:Health News:Not all hospitals treat elderly the same 2Health News:Emergency Care May Be Key to Hospital Readmissions 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 2Health News:U.S. Serves Up New Nutrition Guidelines on 'MyPlate' 3Health News:ASCO: Emerging trends in radiation therapy for women over 70 with early stage breast cancer 2Health News:UofL researchers uncover mechanism in saliva production 2Health News:Obesity Greater Risk for Fatty Liver Than Alcohol, Study Finds 2
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... market research report is available in its catalogue: ... Medical Records http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html ... market for electronic medical records (EMR) for nearly ... comprehensive report of our findings. Our report has ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
(Date:8/19/2014)... KIRKLAND, Wash. , Aug. 19, 2014 ... solutions, will be exhibiting at the 2014 NPPA Summer ... The company will be showcasing its 340B software products ... leader in 340B splitting solutions, supplying over 400 customers ... a range of 340B solutions including its latest solution, ...
Breaking Medicine Technology:EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Talyst Exhibits at the NPPA Summer Conference 2
...   Unigene Laboratories, Inc. (OTCBB: UGNE), today announced ... position of Chief Financial Officer. In this newly created position, ... company,s executive leadership team and lead the strategic direction ... Mr. Moskowitz joins Unigene after spending the previous ...
... 2012 Reportlinker.com announces that a new ... catalogue: Vaccines - ... This market research report package offers ... situation, trends and future outlook for vaccines ...
Cached Medicine Technology:Unigene Appoints David Moskowitz as Chief Financial Officer 2Unigene Appoints David Moskowitz as Chief Financial Officer 3Unigene Appoints David Moskowitz as Chief Financial Officer 4Unigene Appoints David Moskowitz as Chief Financial Officer 5Vaccines - Asia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: